210 related articles for article (PubMed ID: 23093496)
1. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.
Schmidt P; Ritscher L; Dong EN; Hermsdorf T; Cöster M; Wittkopf D; Meiler J; Schöneberg T
Mol Pharmacol; 2013 Jan; 83(1):256-66. PubMed ID: 23093496
[TBL] [Abstract][Full Text] [Related]
2. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor.
Ding Z; Kim S; Kunapuli SP
Mol Pharmacol; 2006 Jan; 69(1):338-45. PubMed ID: 16234484
[TBL] [Abstract][Full Text] [Related]
4. Agonist-bound structure of the human P2Y12 receptor.
Zhang J; Zhang K; Gao ZG; Paoletta S; Zhang D; Han GW; Li T; Ma L; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
Nature; 2014 May; 509(7498):119-22. PubMed ID: 24784220
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.
Mao Y; Zhang L; Jin J; Ashby B; Kunapuli SP
Eur J Pharmacol; 2010 Oct; 644(1-3):10-6. PubMed ID: 20599922
[TBL] [Abstract][Full Text] [Related]
6. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors.
Crepaldi P; Cacciari B; Bonache MC; Spalluto G; Varani K; Borea PA; Kügelgen Iv; Hoffmann K; Pugliano M; Razzari C; Cattaneo M
Bioorg Med Chem; 2009 Jul; 17(13):4612-21. PubMed ID: 19464902
[TBL] [Abstract][Full Text] [Related]
7. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
8. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.
Paoletta S; Sabbadin D; von Kügelgen I; Hinz S; Katritch V; Hoffmann K; Abdelrahman A; Straßburger J; Baqi Y; Zhao Q; Stevens RC; Moro S; Müller CE; Jacobson KA
J Comput Aided Mol Des; 2015 Aug; 29(8):737-56. PubMed ID: 26194851
[TBL] [Abstract][Full Text] [Related]
9. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
von Kügelgen I
Pharmacol Ther; 2006 Jun; 110(3):415-32. PubMed ID: 16257449
[TBL] [Abstract][Full Text] [Related]
11. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y
Garcia C; Maurel-Ribes A; Nauze M; N'Guyen D; Martinez LO; Payrastre B; Sénard JM; Galés C; Pons V
Cell Mol Life Sci; 2019 Feb; 76(3):561-576. PubMed ID: 30406277
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
Ding Z; Kim S; Dorsam RT; Jin J; Kunapuli SP
Blood; 2003 May; 101(10):3908-14. PubMed ID: 12560222
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
Suzuki T; Obara Y; Moriya T; Nakata H; Nakahata N
FEBS Lett; 2011 Dec; 585(24):3978-84. PubMed ID: 22079667
[TBL] [Abstract][Full Text] [Related]
15. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.
Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I
J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of action for reversible P2Y12 antagonists.
Liu H; Ge H; Peng Y; Xiao P; Xu J
Biophys Chem; 2011 May; 155(2-3):74-81. PubMed ID: 21440362
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor.
Deflorian F; Jacobson KA
J Comput Aided Mol Des; 2011 Apr; 25(4):329-38. PubMed ID: 21461952
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes.
Foster HR; Fuerst E; Lee TH; Cousins DJ; Woszczek G
PLoS One; 2013; 8(3):e58305. PubMed ID: 23472176
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and structure of P2Y receptors.
von Kügelgen I; Hoffmann K
Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
[TBL] [Abstract][Full Text] [Related]
20. Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.
Ravi RG; Kim HS; Servos J; Zimmermann H; Lee K; Maddileti S; Boyer JL; Harden TK; Jacobson KA
J Med Chem; 2002 May; 45(10):2090-100. PubMed ID: 11985476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
